Targeting the IL-22/IL-22BP axis enhances tight junctions and reduces inflammation during influenza infection

Hebert, Kelly D.; McLaughlin, Nathan; Galeas-Pena, Michelle; Zhang, Z; Eddens, Taylor; Govero, A; Pilewski, Joseph M.; Kolls, Jay K.; Pociask, Derek

doi:10.1038/s41385-019-0206-9

Cited by 44 publications

(42 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, deletion of IL-22BP negative regulation of IL-22 was shown to decrease lung inflammation and injury compared with WT mice after influenza infection (27). Increased tight junction protein expression was observed in vivo.…”

Section: Influenza Infectionmentioning

confidence: 88%

IL-22 Plays a Critical Role in Maintaining Epithelial Integrity During Pulmonary Infection

Alcorn

2020

Front. Immunol.

View full text Add to dashboard Cite

Pulmonary infection is a leading cause of hospitalization in world. Lung damage due to infection and host mediated pathology can have life threatening consequences. Factors that limit lung injury and/or promote epithelial barrier function and repair are highly desirable as immunomodulatory therapeutics. Over the last decade, interleukin−22 has been shown to have pulmonary epithelial protective functions at the mucosal immune interface with bacterial and viral pathogens. This article summarizes recent findings in this area and provides perspective regarding the role of IL-22 in mucosal host defense.

show abstract

Section: Influenza Infectionmentioning

confidence: 88%

IL-22 Plays a Critical Role in Maintaining Epithelial Integrity During Pulmonary Infection

Alcorn

2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…ILC3 cell production of IL-22 impedes infection with rotavirus, an enteric pathogen that targets IECs, and loss of ILC3 cells or IL-22 increases viral load (Hernández et al, 2015; Zhang et al, 2014). Inflammation following influenza viral infection is exacerbated in IL-22–deficient mice (Ivanov et al, 2013) and reduced in IL-22BP–deficient animals (Hebert et al, 2020). Although there is no direct effect on viral load in IL-22–deficient mice in comparison with controls, susceptibility to inflammation and secondary bacterial infection is increased following influenza clearance in the absence of IL-22 (Ivanov et al, 2013).…”

Section: Role Of Il-22 In Antimicrobial Defense and Dysbiosismentioning

confidence: 99%

The role of IL-22 in intestinal health and disease

Keir¹,

Yi²,

Lu³

et al. 2020

Journal of Experimental Medicine

291

160

View full text Add to dashboard Cite

The cytokine interleukin-22 (IL-22) is a critical regulator of epithelial homeostasis. It has been implicated in multiple aspects of epithelial barrier function, including regulation of epithelial cell growth and permeability, production of mucus and antimicrobial proteins (AMPs), and complement production. In this review, we focus specifically on the role of IL-22 in the intestinal epithelium. We summarize recent advances in our understanding of how IL-22 regulates homeostasis and host defense, and we discuss the IL-22 pathway as a therapeutic target in diseases of the intestine, including inflammatory bowel disease (IBD), graft-versus-host disease (GVHD), and cancer.

show abstract

“…In humans with metabolic syndrome, fibre intake positively correlated with circulating interleukin (IL)‐22 levels 117 . IL‐22 reduces goblet cell hyperplasia in murine AAD models 118,119 and improves epithelial barrier function in both influenza virus and secondary S pneumoniae infection 120,121 . However, a direct relationship between fibre intake, the microbiome and maintenance of the mucous barrier through induction of IL‐22 has yet to be demonstrated, and IL‐22 and microbiome changes may have pathogenic roles in COPD 1,2,15,122 …”

Section: Macronutrients: Impact On Microbiome and Mucous Barriermentioning

confidence: 99%

Impact of diet and the bacterial microbiome on the mucous barrier and immune disorders

Alemao

Budden

Gomez

et al. 2020

Allergy

View full text Add to dashboard Cite

The prevalence of chronic immune and metabolic disorders is increasing rapidly. In particular, inflammatory bowel diseases, obesity, diabetes, asthma and chronic obstructive pulmonary disease have become major healthcare and economic burdens worldwide. Recent advances in microbiome research have led to significant discoveries of associative links between alterations in the microbiome and health, as well as these chronic supposedly noncommunicable, immune/metabolic disorders. Importantly, the interplay between diet, microbiome and the mucous barrier in these diseases has gained significant attention. Diet modulates the mucous barrier via alterations in gut microbiota, resulting in either disease onset/exacerbation due to a “poor” diet or protection against disease with a “healthy” diet. In addition, many mucosa‐associated disorders possess a specific gut microbiome fingerprint associated with the composition of the mucous barrier, which is further influenced by host‐microbiome and inter‐microbial interactions, dietary choices, microbe immigration and antimicrobials. Our review focuses on the interactions of diet (macronutrients and micronutrients), gut microbiota and mucous barriers (gastrointestinal and respiratory tract) and their importance in the onset and/or progression of major immune/metabolic disorders. We also highlight the key mechanisms that could be targeted therapeutically to prevent and/or treat these disorders.

show abstract

Targeting the IL-22/IL-22BP axis enhances tight junctions and reduces inflammation during influenza infection

Cited by 44 publications

References 49 publications

IL-22 Plays a Critical Role in Maintaining Epithelial Integrity During Pulmonary Infection

IL-22 Plays a Critical Role in Maintaining Epithelial Integrity During Pulmonary Infection

The role of IL-22 in intestinal health and disease

Impact of diet and the bacterial microbiome on the mucous barrier and immune disorders

Contact Info

Product

Resources

About